

ADVANCES IN CERVICAL CANCER PREVENTION

PreTect® HPV-Proofer 7

Finding clinically relevant answers!



HPV infections are
common but > 90% are
harmless¹

THE CHALLENGE IS
ON: FIND THE
INFECTIONS
THAT MATTER

CLINICAL BENEFITS OF USING PreTect® HPV-Proofer 7

- Risk stratification and direct genotyping
- E6/E7 mRNA expression from HPV 16, 18, 31, 33, 45, 52 and 58
- Identification of cervical precursors most likely to progress to invasive cancers
- Accurate patient management, triaging HPV DNA positive women/low grade cytology
- Enhanced identification of cervical adenocarcinoma
- Minimization of unnecessary referral and over-treatment
- Suitable even in young women

PreTect[®] HPV-Proofer 7

Background

Cervical cancer is caused by the continuous overexpression of the E6/E7 oncogenes from high-risk HPV virus types²⁾

Almost 80% of women have an HPV infection during their life, but most infections are harmless and resolve spontaneously


More than 100 HPV types are known but only a few lead to high-grade precancerous lesions and cervical cancer

Screening needs high specificity and accurate patient management to minimize the risk of unnecessary follow-up of false positive cases

TEST INFORMATION

| | |
|--------------------------------|--|
| Individual HPV genotyping | E6/E7 mRNA HPV 16, 18, 31, 33, 45, 52, and 58 |
| Intrinsic Sample Control (ISC) | Targeting mRNA from housekeeping gene |
| Sample type | Cervical samples |
| Storage media | PreTect TM (PreTect AS); PreservCyt; SurePath |
| Input material: | Isolated Nucleic Acid (DNA/RNA)* |
| Technology | Real-time NASBA isothermal amplification (41°C) with four specific molecular beacon probes |
| Format | 96-well PCR plate pre-filled with reagents n=94 |
| Assay time | ~ 150 minutes |
| Instrumentation | Fluorescence reader / RT-PCR (CFX-96/QuantStudio5) |

* DNA/RNA isolation reagents not included.




Key facts

- A qualitative CE-IVD kit to identify the few women who are at highest risk for cervical disease
- Selective mRNA amplification; identification of carcinogenic activity, not viral presence
- Unique risk stratification and genotyping

References:

- 1) Elfgrén et al (2000) Am J Obstet Gynecol **183** (3):561-567
- 2) Zur Hausen H (2002) Nat Rev Cancer **2** (5):342-350. Review



Contact us for further information!

PreTect AS

Ustadhagan 8 | N-3490 Klokkestua | Norway
Tel: +47 32 79 88 00 | www.prect.no
E-mail: prect@prect.no